Philip P Boudreau bought $201k of ABT
EVP AND CFO at ABBOTT LABORATORIES. 2,200 shares at an average of $91.50, traded Apr 23, 2026, filed Apr 27, 2026.
Score components
- +22RoleCFO
- +12Trade size$201k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +18Price context1% above the 52-week low; 32% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.7%, 3m +13.4%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001805099-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | IDiscretionary transaction Common shares without par valueindirect: Profit Sharing Trust | +8,909 | $92.04 | $820k | 9,276 | Apr 27, 2026 |
| Apr 23, 2026 | POpen-market purchase Common shares without par valueindirect: By Spouse | +2,200 | $91.50 | $201k | 2,200 | Apr 27, 2026 |
Related signals
Other insiders at ABBOTT LABORATORIES and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | ABBOTT LABORATORIES | John A. McCoy Jr. VICE PRESIDENT AND CONTROLLER | $2,958 27 shares | -0% | |
| 70Notable | ABBOTT LABORATORIES | Robert B Ford CHAIRMAN AND CEO | $46M 398,832 shares | -57% | |
| 43Moderate | ABBOTT LABORATORIES | Louis H. Morrone EXECUTIVE VICE PRESIDENT | $643k 5,850 shares | -8% | |
| 62Notable | ABBOTT LABORATORIES | John G Stratton director | $174k 2,000 shares | +9% | |
| 72Notable | ABBOTT LABORATORIES | Daniel J Starks director | $927k 10,000 shares | +0% | |
| 40Moderate | ABBOTT LABORATORIES | Daniel Gesua Sive Salvadori EVP AND GROUP PRESIDENT | $102k 885 shares | -1% | |
| 48Moderate | ABBOTT LABORATORIES | John A. McCoy Jr. VICE PRESIDENT AND CONTROLLER | $68k 585 shares | -2% | |
| 48Moderate | ABBOTT LABORATORIES | Mary K Moreland EXECUTIVE VICE PRESIDENT | $71k 613 shares | -1% | |
| 51Moderate | ABBOTT LABORATORIES | Louis H. Morrone EXECUTIVE VICE PRESIDENT | $132k 1,144 shares | -1% | |
| 39Weak | ABBOTT LABORATORIES | Eric Shroff Senior Vice President | $82k 709 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.